Novo Nordisk A/S is rated Buy with Wegovy pill seen as a potential catalyst to reignite growth & recapture market share. Read ...
Dec 23 (Reuters) - The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's weight-loss drug Wegovy could potentially expand access to millions of patients and give the ...
Novo Nordisk is my top opportunity for 2026, driven by multiple catalysts and a compelling valuation. The Wegovy pill's FDA ...
CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...
Novo Nordisk's latest quarterly update disappointed investors -- again. But the company has a lot going on behind the scenes that affects its outlook. Between a strong pipeline and a reasonable ...
Semaglutide failed to demonstrate slowed Alzheimer’s progression in EVOKE/EVOKE+ preliminary results, though some biomarkers improved. Stock plunged intraday, then partly recovered; shares are down ...
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Dec 23 (Reuters) - The U.S. Food and Drug Administration's approval of an oral version of Novo Nordisk's (NOVOb.CO), opens new tab weight-loss drug Wegovy could potentially expand access to millions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback